Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tryptamine Therapeutics ( (AU:ENP) ) has shared an update.
Entropy Neurodynamics Limited has applied to the ASX for quotation of 1,931,012 new fully paid ordinary shares, issued on 16 January 2026 as non‑cash remuneration to directors in lieu of fees, pursuant to shareholder approval granted at the company’s November 2025 annual general meeting. The move modestly increases the company’s share count while conserving cash, signalling a continued emphasis on aligning director incentives with shareholders and preserving balance-sheet flexibility in a capital‑constrained environment.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, listed on the ASX under the code ENP, operates in the broader neuroscience and neurotechnology sector, although the filing does not detail its specific products or services. As an ASX-listed entity, it is subject to Australian securities market regulations and corporate governance requirements, including shareholder approvals for director remuneration in equity.
Average Trading Volume: 2,158,840
Technical Sentiment Signal: Sell
Current Market Cap: A$51.5M
For a thorough assessment of ENP stock, go to TipRanks’ Stock Analysis page.